OPEN LETTER
Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system.

[version 1; peer review: 3 approved]

Diptesh Aryal\textsuperscript{1,1*}, Abi Beane\textsuperscript{2,3,2*}, Arjen M. Dondorp\textsuperscript{2,3,2*}, Cameron Green\textsuperscript{4,4*}, Rashan Haniffa\textsuperscript{2,3,2*}, Madiha Hashmi\textsuperscript{5,5*}, Devachandran Jayakumar\textsuperscript{6,7,6*}, John C. Marshall\textsuperscript{8,8*}, Colin J. McArthur\textsuperscript{9,10,9*}, Srinivas Murthy\textsuperscript{11,11*}, Steven A. Webb\textsuperscript{4,12,13,14,14*}, Subhash P. Acharya\textsuperscript{15}, Pramodya G. P. Ishani\textsuperscript{15}, Issrah Jawad\textsuperscript{15}, Sushil Kanal\textsuperscript{16}, Kanchan Koirala\textsuperscript{1}, Subekshya Luitel\textsuperscript{17}, Upulee Pabasara\textsuperscript{15}, Hem Raj Paneru\textsuperscript{18,18*}, Ashok Kumar\textsuperscript{19}, Shoaib Siddiq Patel\textsuperscript{20}, Nagarajan Ramakrishnan\textsuperscript{7}, Nawal Salahuddin\textsuperscript{21}, Mohiuddin Shaikh\textsuperscript{20}, Timo Tolppa\textsuperscript{15}, Ishara Udayanga\textsuperscript{15}, Zulfiqar Umran\textsuperscript{22}

\textsuperscript{1}Critical Care and Anaesthesia, Nepal Mediciti Hospital, Lalitpur, Bagmati Pradesh, 44600, Nepal
\textsuperscript{2}Critical Care, Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Central Thailand, 10400, Thailand
\textsuperscript{3}Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
\textsuperscript{4}Australian and New Zealand Intensive Care Research Centre, School of Epidemiology and Preventive Medicine Monash University, Melbourne, Victoria, Australia
\textsuperscript{5}Department of Critical Care, Ziauddin University, Karachi, Sindh, Pakistan
\textsuperscript{6}Chennai Critical Care Consultants, Chennai, Tamil Nadu, 600 040, India
\textsuperscript{7}Critical Care Medicine, Apollo Speciality Hospital OMR, Chennai, Tamil Nadu, India
\textsuperscript{8}The Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Ontario, Canada
\textsuperscript{9}Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand
\textsuperscript{10}Medical Research Institute of New Zealand, Wellington, New Zealand
\textsuperscript{11}Faculty of Medicine, University of British Columbia School of Medicine, Vancouver, British Columbia, Canada
\textsuperscript{12}School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia
\textsuperscript{13}St John of God Hospital, Subiaco, Western Australia, Australia
\textsuperscript{14}Critical Care Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Bagmati Pradesh, 44600, Nepal
\textsuperscript{15}National Intensive Care Surveillance- MORU, Borella, Colombo, Western Province, 08, Sri Lanka
\textsuperscript{16}Critical Care Medicine, Grande International Hospital, Kathmandu, Bagmati Pradesh, 44600, Nepal
\textsuperscript{17}Nepal Intensive Care Foundation, Kathmandu, Bagmati Pradesh, Nepal
\textsuperscript{18}Pulmonary and Critical Care, Hospital for Advanced Medicine and Surgery, Kathmandu, Bagmati Pradesh, Nepal
\textsuperscript{19}Department of Chest Medicine and Critical Care, Ziauddin University, Karachi, Sindh, Pakistan
\textsuperscript{20}South East Asian Research in Critical care and Health, Remedial Centre Hospital, Karachi, Sindh, Pakistan
\textsuperscript{21}Pulmonary & Critical Care Medicine, National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan
\textsuperscript{22}Office of Research, Innovation & Commercialization (ORIC), Ziauddin University, Karachi, Pakistan

\* Equal contributors

\textbf{First published:} 28 Jan 2021, 6:14
\url{https://doi.org/10.12688/wellcomeopenres.16486.1}
Abstract
The Randomized Embedded Multifactorial Adaptive Platform (REMAP-CAP) adapted for COVID-19) trial is a global adaptive platform trial of hospitalised patients with COVID-19. We describe implementation in three countries under the umbrella of the Wellcome supported Low and Middle Income Country (LMIC) critical care network: Collaboration for Research, Implementation and Training in Asia (CCA). The collaboration sought to overcome known barriers to multicentre-clinical trials in resource-limited settings. Methods described focused on six aspects of implementation: i, Strengthening an existing community of practice; ii, Remote study site recruitment, training and support; iii, Harmonising the REMAP CAP- COVID trial with existing care processes; iv, Embedding REMAP CAP- COVID case report form into the existing CCA registry platform, v, Context specific adaptation and data management; vi, Alignment with existing pandemic and critical care research in the CCA. Methods described here may enable other LMIC sites to participate as equal partners in international critical care trials of urgent public health importance, both during this pandemic and beyond.

Keywords
Pandemic, clinical trials, research network, registry platform, LMICS, capacity building.
Corresponding author: Abi Beane (abi@nicslk.com)

Author roles: Aryal D: Investigation, Supervision, Validation, Writing – Review & Editing; Beane A: Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Dondorp AM: Conceptualization, Funding Acquisition, Investigation, Project Administration, Supervision, Validation, Writing – Review & Editing; Green C: Project Administration, Validation, Writing – Review & Editing; Haniffa R: Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Project Administration, Software, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Hashmi M: Investigation, Methodology, Project Administration, Validation, Writing – Review & Editing; Jayakumar D: Investigation, Project Administration, Validation, Writing – Review & Editing; Marshall JC: Supervision, Writing – Review & Editing; McArthur CJ: Conceptualization, Project Administration, Supervision, Validation, Writing – Review & Editing; Murthy S: Supervision, Writing – Review & Editing; Webb SA: Conceptualization, Funding Acquisition, Project Administration, Supervision, Validation, Writing – Review & Editing; Acharya SP: Investigation; Ishani PGP: Investigation, Software, Validation; Jawad I: Data Curation, Investigation, Methodology, Project Administration, Software, Validation, Visualization; Khanal S: Investigation; Koirala K: Investigation; Luitel S: Investigation; Pabasara U: Data Curation, Investigation, Software, Validation; Paneru HR: Investigation; Kumar A: Investigation; Pateli SS: Investigation; Ramakrishnan N: Investigation; Salahuddin N: Investigation; Shaikh M: Investigation; Tolppa T: Investigation; Udayanga I: Data Curation, Investigation, Methodology, Software, Validation; Umrani Z: Investigation

Competing interests: No competing interests were disclosed.

Grant information: The project CRIT Care Asia is funded by Wellcome Innovations grant awarded to Oxford University, Professor AM Dondorp (PI), Grant Award Code: 215522. Funding for CCA sites to participate in the REMAP trial is provided by the Minderoo Foundation.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Aryal D et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Aryal D, Beane A, Dondorp AM et al. Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system. [version 1; peer review: 3 approved] Wellcome Open Research 2021, 6:14 https://doi.org/10.12688/wellcomeopenres.16486.1

First published: 28 Jan 2021, 6:14 https://doi.org/10.12688/wellcomeopenres.16486.1
Introduction
COVID-19 in LMICs
A truly global pandemic, the COVID-19 pandemic has placed unprecedented strain on national health systems globally, with demand for intensive care beds and mechanical ventilators rapidly outstripping their availability, even in relatively highly resourced settings. The consequences for low- and middle-income settings, where the quality and availability of health care and related resources (including oxygen, and mechanical ventilation) is typically poorer and where limited pre-pandemic data is available to inform priorities for research, are potentially devastating. With steroids and possibly IL6 receptor antagonists the exceptions, survival from severe COVID-19 remains dependent on providing the best possible supportive care. Recommendations for supportive therapies are derived mainly from resource-rich settings, whereas recommendations for resource-poor settings in low- and middle-income countries (LMICs), or for rich countries with health systems overwhelmed by the pandemic, are largely lacking.

Barriers to clinical trials in LMICs
Developing countries represent the majority of the world’s population and host nearly 90% of the worldwide burden of disease, with communicable diseases including lower respiratory tract infections the prevailing causes for loss of life and disability in low socio-demographic Index (SDI) countries. High quality clinical research, codesigned and conducted in low SDI countries and in resource constrained LMICs is required in order to discover or verify both the efficacy and effectiveness of treatments in diverse settings. Despite this, LMICs remain severely underrepresented in clinical research - and specifically in clinical trials. Those stakeholders from LMICs seeking to undertake research often face barriers to successful trial participation; limited expertise or infrastructure to conduct research, lack of financial and human resources and lack of peer to peer support, and complex ethical and regulatory processes- which to navigate costs both time and energy for already overburdened clinicians.

REMAP: A platform trial
REMAP-CAP, the Randomised Embedded Multifactorial Adaptive Platform Trial in Community-Acquired Pneumonia (ClinicalTrials.gov ID NCT02735707), is a trial that studies multiple interventions simultaneously and sequentially for patients with severe community acquired pneumonia (CAP) admitted to the intensive care unit (ICU). Its adaptive statistical methods including response-adaptive randomisation enable rapid uptake of study results, meaning patients may benefit from the accruing data. Following the COVID-19 outbreak, REMAP-CAP activated its pandemic mode to focus on treatments for COVID-19 disease in the most critically ill patients. Since the global pandemic in March 2020 REMAP has increased its sites five-fold, internationally.

Collaboration for Research, Implementation and Training in Critical Care in Asia (CCA)
Wellcome - Mahidol Oxford Tropical Medicine Research Unit supported CCA is a LMIC-led collaborative spanning nine Asian countries. Its goal is to improve outcomes for critically ill patients, using near real-time high-quality data captured through a cloud-based registry platform to enable setting prioritised improvement, training and research. At its core, the CCA brings together clinical, research, data science and quality improvement stakeholders, who together work to support fledgling acute and critical care registries. The CCA connects over 95 intensive care units from institutions to provide diverse high-quality data to generate evidence and feedback in near real time for service improvement and research, akin to the foundations of a learning health system (LHS).

Aim
We leveraged the CCA registry platform and existing infrastructure to operationalise REMAP-CAP for COVID and non COVID domains in LMIC ICUs. We sought to overcome the known barriers to operationalising clinical trials in LMICs. Six key aspects of this process are described: i) strengthening an existing community of practice; ii) enabling remote study site recruitment, training and support; iii) harmonising the REMAP trial with existing care processes; iv) embedding REMAP into the existing CCA registry platform; v) providing context specific adaptation and data management, vi) aligning with existing pandemic and critical care research in the CCA.

Approach
Strengthening an existing community of practice
We leveraged existing knowledge and expertise within the CCA and adopted a “learning by doing” approach. Stakeholders who included clinicians, researchers, microbiologists, policy makers and laboratory/ procurement services met online to discuss the REMAP-CAP vision and the feasibility of specific trial domains. The national leads and REMAP-CAP International Trial Steering Committee (ITSC) jointly designated the CCA registry team as the central hub for site recruitment training and data coordination in the network sites, providing local ownership and engagement. A regional management committee (CCA RMC) was proposed, consisting of national Principal Investigators (PIs) and members of the CCA from three CCA countries (India, Nepal and Pakistan) where CCA supported critical care registries are now well established and where governance pathways for data collection and sharing as part of the CCA is already established.

National PIs then together with the CCA RMC and ITSC reviewed the trial protocols and identified potential country and site specific ethical and regulatory bottlenecks. Network members with expertise in navigating ethical and regulatory approval for trials in Asia, provided templates for ethical applications, along with past reviewer questions and the corresponding responses, enabling system memory, shared learning and reducing the burden/ duplication of work for local investigators. Existing REMAP-CAP core protocol documentation and appendices for each domain provided modular, stepwise resources that were presented to national regulatory committees, providing context and precedent for the REMAP trial. The iterative approach process allowed for learning a great deal about trial implementation in diverse regions while ensuring local ownership and engagement was a major focus.
Remote site onboarding
The already-established CCA registry team—project coordinators, research assistants and data analysts, in partnership with national PIs, clinical leads, site level data collectors and clinical research nurses—were essential to operationalize REMAP. Stakeholders in existing CCA sites keen to participate in the trial were approached. Previous trial participation was not a requirement, but an established track record of registry data capture for evaluating existing care was. The CCA team, who already provide support to sites in the network with data quality, curation, and analysis, worked closely with the international REMAP trial team to train the multidisciplinary site level study teams in patient recruitment, consent and study monitoring protocols. The training was delivered online using audiovisual communication mechanisms and leveraged existing international REMAP-CAP resources of training videos. Following training, the central CCA team monitors ongoing trial recruitment and reporting from each site, providing remote support for troubleshooting for technical or research issues. Weekly meetings with the national coordinators using the logs (as described above) offers an opportunity to feedback site level learning and monitor protocol deviations, which are reported through the registry platform. Leveraging existing CCA remote support and communication channels for trial coordination has been especially important given both current COVID pandemic and the geographic distance that the CCA covers.

Harmonisation with existing care processes
The REMAP design is that the trial research activities and existing clinical care are synergistic. This design aims to streamline research processes and embed them within existing care. This design approach is especially important both in resource constrained health care settings, and during pandemics where trial coordination and research specific activities can at best place additional burden on already exhausted healthcare providers and at worst distract or divert clinicians away from front line care. Two domains; anticoagulation for COVID-19 patients and Vitamin C for severe respiratory illness patients were selected based on their synergy with population specific research priorities, their existing use in clinical care of critically ill COVID and non-COVID respiratory illness patients, and existing availability of the therapeutic agents. National leads and the CCA RMC then worked with site level stakeholders to ensure trial therapeutics and bioclinical sampling within existing supply chain and laboratory services. Trial domains and data points were reviewed, and all (currently 12) recruited centers selected have the necessary laboratory services in place, removing the need for additional trial-specific laboratory resources. Treatments within the two selected domains are already available in the participating centers, meaning additional drug procurement, shipping and storage for the trial was not needed.

Embedding REMAP into the existing CCA registry platform
The REMAP-CAP and CCA teams have integrated the REMAP trial domain specific Case Report Forms (CRF) into the CCA registry, ensuring interoperability of data through harmonisation with existing REMAP data structure and CRF logic (Figure 1). To achieve this, the domain specific CRFs have been mapped to existing case mix, disease severity and prediction, clinical outcomes, and processes of care data points already captured as part of the CCA registry platform.

To facilitate patient screening, enrollment, and consent, the REMAP CCA has added automated alerts in the participating sites for all severe acute respiratory illness patients as they are entered into the registry alerting data collectors and the research team of a patient’s potential eligibility for the trial. The patient eligibility and randomization—arguably one of the most complex aspects of the adaptive trial design—is undertaken in the existing REMAP spinnaker system. The randomisation platform9, embedded in the CCA registry platform, provides a seamless transition for the bedside research team. Consent forms, study protocols, and participatory information leaflets including contact information for the local, national, and international study teams are all available to view, download and print by registered users from the CCA registry platform. Consent forms, once signed are then photographed and uploaded to the CCA platform, placing all study resources and documentation in a central location, where issues pertaining to enrollment and consent can also be reported to and monitored by the central REMAP CCA team, ensuring Good Clinical Practice criteria are met (Figure 2).

REMAP enrollment completion generates an alert for the central REMAP CCA team, who are then available remotely to support the site level team throughout the study process from enrollment, consent, to patient encounter completion. Once enrolled in the trial, monitoring is all reported through the CCA platform. Existing form structure in the CCA platform follows an ontological approach which mirrors the patient’s journey and prompts the study team to complete forms sequentially. To further ensure in-trial adherence with protocols, successful enrollment of a patient is visible on the patient’s banner bar on their ‘encounter home page’ that indicates the patient’s status, as a context specific adaptation to improve data management of trial participants. Protocol deviations and adverse events are reported through the web-based forms which are then emailed directly to the international REMAP trial coordination team.

Context specific adaptation and data management
The existing CCA registry data structure allows for site specific variation, with a common data dictionary to enable transformation of data before export11. Study variables such as laboratory tests are reported in the intensive care units’ routine unit of measurement. Terminology and data collection time points have been harmonised with already proven registry data collection practices. The CCA platform’s existing internal data quality mechanisms—field completeness, value range validity and branching logic— all reported through descriptive analytic dashboards promote data quality by prompting users towards completeness and alerting to missed or potential spurious responses. Similarly logs of screening, patient recruitment and study monitoring are visible to the REMAP CCA team national trial leads and the international REMAP project coordinator.
Figure 1. Integration of the REMAP trial domain specific Case Report Forms (CRF) into the CCA registry.

Figure 2. CCA team structure and organogram. Critical care network: Collaboration for Research, Implementation and Training in Asia team (CCA) structure.

The registry provides a federated system for data storage, whereby existing national registries house their data- essential for compliance with the national data security requirements (Figure 3). All anonymised registry and trial data is backed up to a central CCA server. Trial-relevant data are continuously and automatically extracted from the CCA registry platform, and curated into a dataset suitable for export to the international data coordinating center at Monash University. Data are stored
Figure 3. CCA data platform structure.

in a MongoDB, processed using a scheduled combination of Javascript, and formatted and exported for trial reporting. An unblinded investigator reviews initial exports in detail to ensure data accuracy. Variables that depend on more than one discrete CRF field (e.g. severity of illness score) are reported as raw values, enabling the international statistical analysis committee to validate source data prior to analysis. Data extracts are reviewed by an unblinded investigator and two programmers. Data once extracted is transferred via a secure file transfer service.

Alignment with existing pandemic and critical care research in the CCA

The COVID-19 pandemic has resulted in unprecedented mobilisation of ministries, policy makers and clinicians to engage in research. In partnership with ISARIC and led by collaborating registry PRICE, the CCA platform has already been adapted to comply with the ISARIC Clinical Characterisation Protocol as part of the coordinated response to pandemic research. Enabled by the CCA platform’s modular structure, common data to ISARIC CCP, REMAP trial and critical care surveillance is entered only once by the bedside registry team. This reduces the burden of data capture and ensures data pertaining to patient care processes for REMAP is also available to the clinical team for site level service evaluation and improvement. The data is then mapped to a common data model (OMOP) as part of the CCA platform’s commitment to the FAIR principles of data management and creating the potential for sites to contribute to other international observational pandemic research.

Impact

The CCA’s and collaborating registries shared expertise, track record in remote working and a prior knowledge of overcoming technical and training barriers to registry adoption was a central tenet of overcoming known barriers to trials described above. Known barriers to trials in resource constrained health systems; technological challenges including internet bandwidth, navigating institutional firewalls, device availability and human computer interaction were mitigated by the infrastructure already established by the CCA. Similarly, the strong partnership of support for real-time troubleshooting already present between the CCA implementation team and collaborating registries was...
invaluable during initial recruitment and training. Embedding the REMAP trial domain CRF’s into the existing registry platform has reduced the burden of data capture for frontline clinical staff; essential in resource constrained settings, where failure to optimise and reuse data results in at best poor quality of data and at worst misdirects resources from clinical care. The CCAs upfront investment in a codesigned platform, developed in partnership with frontline clinicians and iterated within the diverse health systems in the CCA, has mitigated against known challenges of data availability and quality. In addition, leveraging the cloud-based platform with inbuilt data audit and feedback mechanisms has enabled hospitals within the geographically wide network to be supported by a centralised research team. Data generated through the CCA will enable evaluation and benchmarking of existing care practices for patients with pneumonia in intensive care and may inform quality improvement projects to implement and share best practices within the community of practice; the hallmarks of a learning health system. Nine sites in three countries are now actively recruiting patients to pandemic related REMAP trial domains; India, Nepal and Pakistan. Other sites in the CCA network are seeking collaboration and will be supported.

Remaining challenges
Whilst the pandemic has accelerated opportunities for international clinical trial collaboration, particularly amongst clinicians, ethics committees, data sharing committees and research review boards are faced with unprecedented numbers of applications for review. Such committees in many LMICs rely heavily on volunteers, and members may have themselves face rising clinical obligations, which coupled with limited experience of complex trials such as REMAP or of navigating international data sharing- may lead to opportunities to engage in research being rejected or delayed. Collaborations such as CCA, along with grant making bodies, have a duty to further Invest in building capacity for such services and in promoting greater compatibility of governance structures.

Conclusions
Implementation of the REMAP-CAP for COVID trial in the CCA is feasible and facilitated by multidisciplinary collaboration. This investment establishes important groundwork for future learning health system endeavors. This operationalisation of a randomized controlled platform trial in a registry-embedded manner in three countries of a nascent critical care network can be the stimulus for further democratisation of international trial participation.

Data availability
No data are associated with this article.

Author information
The first 11 authors contributed equally and are listed alphabetically.

Acknowledgements
We would like to thank REMAP ITSC which can be found at https://www.remapcap.org/remapcap-itsc, Wellcome Innovations and CRIT Care Asia.

References


Open Peer Review

Current Peer Review Status: ✔️ ✔️ ✔️

Version 1

Reviewer Report 16 February 2021

https://doi.org/10.21956/wellcomeopenres.18151.r42371

© 2021 Lipnick M et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Michael Lipnick
Center for Health Equity in Surgery and Anesthesia, Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, CA, USA

Sky Vanderberg
University of California San Francisco, San Francisco, CA, USA

This article focuses on an important topic in clinical research - the underrepresentation of LMICs in clinical research/trials. This article describes the implementation of the REMAP-CAP study and CCA collaboration as impressive examples of how to promote equitable and context-relevant research.

Overall the manuscript is excellent though could benefit from some additional copyediting. Please find additional minor comments for consideration and revision below:

Introduction:
- The terms low SDI and LMIC are both used independently and in combination - consider streamlining terminology.
- May be helpful to make the point that interventions designed/implemented for respiratory failure in well-resourced settings have the potential to cause harm when applied in LMICs (i.e. mechanical ventilation) without other considerations in place.
- Consider expanding on the reference/origin for 'known barriers' to operationalising clinical trials in LMICs or expanding on the process that identified the 'six key aspects' of the process.
- When discussing REMAP-CAP trial design, consider further clarifying how study patients benefit from the response-adaptive randomization in near real time.
- Second sentence in Collaboration for Research, Implementation and Training (CCA) section needs clarification.
**Approach:**
- Strengthening an existing community of practice section: Consider expanding on the lasting positive effects of this endeavor. Specifically, what was learned/gained during this process that will facilitate future inclusion of LMIC sites in international clinical trials.
  - Consider expanding on how the CCA model of remote onboarding/monitoring can be replicated elsewhere.
  - Harmonisation with existing care processes section: consider clarifying the message in the first sentence.
  - Context specific adaptation and data management section: Consider additional citations to specify the “already proven registry data collection practices.”

**Impact:**
- First paragraph: Could you present quantifiable data such as percent completeness, any audit data as available, to underscore the degree of impact.
  - Remaining challenges section: Consider clarifying the wording of the first sentence, as we do not know which groups are faced with accelerated opportunities vs unprecedented numbers of applications.
  - Please expound upon remaining challenges, as bottlenecks at ethics/regulatory committees are likely not the only remaining challenges for this type of work.

**Conclusions:** Could consider also highlighting the scientific merit to include LMIC sites in international critical care clinical trials.

**Figure/Tables:**
**Figure 2.**
- Please consider including figure legend to specify the significance of dotted lines, red circles in “academic community” box, greyed-out boxes, and lines which have arrows in opposite directions (?bidirectional).

**Figure 3.**
- Consider color coding to further delineate data flow in the direction of national registries to CCA database from reports/analytics flow in the direction of CCA data to national registries.
- Define “ETL” in legend.

**Is the rationale for the Open Letter provided in sufficient detail?**
Yes

**Does the article adequately reference differing views and opinions?**
Yes

**Are all factual statements correct, and are statements and arguments made adequately**
supported by citations?
Yes

Is the Open Letter written in accessible language?
Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: ARDS, research in HIC-LMIC collaborations

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 12 February 2021

https://doi.org/10.21956/wellcomeopenres.18151.r42370

© 2021 Riviello E. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Elisabeth Riviello
1 Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
2 Harvard Medical School, Boston, MA, USA

Major comments

This is a really important and well-structured manuscript, providing a detailed description of how a regional international ICU registry was used to make international trial participation feasible for three LMICs. The detail provided is incredibly helpful as readers think about applying the lessons learned by this group.

In particular the following descriptions were helpful: use of the community of practice for IRB navigation; using the CCA structure and REMAP resources to onboard remote sites; choosing interventions that are feasible for the resources at the sites in question; embedding every part of the CRF and consent into the CCA registry; and a very detailed description of the data management processes.

One barrier I would love to see addressed is compensation for time spent, including both PIs as well as data collectors. Often international trials expect sites to provide leadership (PIs) and data collection, with little or no compensation. This is far less feasible in LMICs, where clinicians are
already stretched, as noted in the manuscript. A description of how time is compensated (or not) for the baseline registry, and whether the REMAP-CAP trial added resources to this, would be very helpful. If the answer is that compensation is largely not provided, this is also interesting information – and would suggest that the registry is so useful to clinicians that the time spent entering data is considered part of clinical care time. Any detail that can be provided on this would be a welcome addition. However, the authors are certainly not required to add comments on this, as it may not be a relevant learning point from their experience.

Overall the manuscript could benefit from copy editing, particularly in shortening some lengthy sentences, and adding and deleting commas to improve clarity.

Minor comments
Title:
○ If allowed by Wellcome formatting rules, I would add the acronym (REMAP-CAP) after the full name in the title, as this is a well-known trial group, recognized more easily by its acronym name.

Abstract:
○ It is not obvious how CCA is the acronym for the group as spelled out (would add back in the “Critical Care” part, for the “CC” of the acronym).

○ A dash is not needed between centre-clinical. Instead, there could be a dash in multi-centre.

○ Would say “Methods described focus” rather than “Methods described focused”.

○ Would use usual numbering: 1) or i) rather than i,

○ No need to capitalize the implementation areas described

Introduction
○ I would provide citations for: 1) the statement of scarcity of resources even in highly-resourced areas and 2) the mention of steroids and IL-6 inhibitors as evidence-based treatments for COVID-19.

○ Would say “bear ...” rather than “host ...”

○ “High quality clinical research ... in low SDI countries and in resource constrained LMICs” ... are the authors meaning say that low SDI countries and LMICs are distinct from one another? If not, it would be better to use only one of these as the descriptor of resource-limited settings.

○ “successful trial participation” should be followed by a colon rather than a semicolon.

○ “Those stakeholders from LMICs seeking to undertake ...” is a long sentence, and would benefit from shortening, particularly the last parenthetical about the time and energy required for regulatory processes.
“REMAP: a platform trial”: I would cite the description noted in the first sentence; even citing the REMAP-CAP website would be sufficient.

“CCA”: I would start the first sentence of this section with “The” before “Wellcome-Mahidol ...”.

“CCA”: I would add a citation for the sentence describing CCA; the website for CCA would be sufficient.

Figure 3:
- This would be even more useful if REMAP-CAP were mentioned, diagramming at what point in the process the data goes to the REMAP-CAP group.

**Is the rationale for the Open Letter provided in sufficient detail?**
Yes

**Does the article adequately reference differing views and opinions?**
Yes

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**
Partly

**Is the Open Letter written in accessible language?**
Partly

**Where applicable, are recommendations and next steps explained clearly for others to follow?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** global health, resource-poor settings, critical care, ARDS, sepsis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Paul Young  
Medical Research Institute of New Zealand, Wellington, New Zealand

This is a very clear account of an important and impressive piece of work implementing a complex global trial within an existing registry. It provides a blueprint for future efforts to involve LMICs in international critical care trials. The article is scientifically sound and I have no suggestions for changes except that "data is" should be changed to "data are" because the singular form of data is datum.

Is the rationale for the Open Letter provided in sufficient detail?  
Yes

Does the article adequately reference differing views and opinions?  
Yes

Are all factual statements correct, and are statements and arguments made adequately supported by citations?  
Yes

Is the Open Letter written in accessible language?  
Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?  
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** intensive care medicine

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.